Moderna Inc MRNA reportedly is close to signing a coronavirus vaccine deal with Israel, a testament to the validity and viability of the company's vaccine program.
What Happened: The vaccine deal, which is reportedly in advanced stages of discussion, was reported by Israeli news site Ynet Sunday, quoting unnamed officials at the Israeli Health Ministry.
Moderna is among the frontrunners in the race for developing a vaccine for the novel coronavirus. The Cambridge, Massachusetts-based company said last week that it has finalized the protocol for a late-stage study that will evaluate 30,000 volunteers.
A preprint of animal data showed that the vaccine generated potent neutralizing activity and protected the mice from viral infection up to 13 weeks post-injection. The findings showed no safety signals.
What's Next: Moderna is set to start a Phase 3 trial shortly, while the Phase 1 and 2 studies are ongoing. The company has funding from BARDA and has also put manufacturing tie-ups in place.
At last check, Moderna shares were rising 5.79% to $65.59.
Related Links:
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx
Sinovac Makes Headway In Coronavirus Vaccine Race With Positive Preliminary Phase 1/2 Results
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
